Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15

뉴스 본문을 불러오고 있어요.

Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15 | 웨이프 WAPE

Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15

기사 요약

관련 종목

댓글 —